Author Archives: Marisa Wexler MS

EU Committee Recommends Approval of Tavneos for Severe, Active AAV

A committee of the European Medicines Agency has recommended approving Tavneos (avacopan) as an add-on therapy for adults with severe, active microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA), the two most common types of ANCA-associated vasculitis. This recommendation from the Committee for Medicinal Products for Human Use…

Researchers Call for New System to Better Classify Vasculitis

A new classification system, based on the underlying cause of disease, may be necessary to better understand ANCA-associated vasculitis (AAV) and other disorders characterized by inflammation in the blood vessels. That’s according to a team led by scientists at Aarhus University, in Denmark, who published their idea for the…

Low-dose Rituximab May Be Effective in Preventing Relapses

A reduced dosage of rituximab maintenance therapy may be effective at preventing relapses among people with ANCA-associated vasculitis (AAV), a new study reports. Specifically, the researchers said 500 mg infusions every six months “appear to be an effective and safe option” for maintaining AAV remission. “This study provides real-world…

Abstract on How Avacopan Affects Kidney Function Makes Top 10 List

Treatment with ChemoCentryx’s investigational therapy avacopan can improve kidney function in people with ANCA-associated vasculitis to a greater extent than steroids, especially among individuals with advanced kidney disease, clinical trial data show. The data were presented at the annual meeting of the European Renal Association –…

Factors Predicting Serious AAV Infections Found to Vary Over Time

The risk factors that predict serious infections in people with ANCA-associated vasculitis (AAV) vary with time, a study found. Factors associated with early infection include age and admission to an intensive care unit, whereas kidney function is the most important risk factor for late infections, the investigators said. The…